|By PR Newswire||
|November 7, 2012 03:24 PM EST||
BOSTON, Nov. 7, 2012 /PRNewswire/ --
- ARI-3037MO was well tolerated in single and repeat ascending dose trials in healthy volunteers
- ARI-3037MO did not provoke flushing or any other treatment-related adverse effects in 58 healthy male and female volunteers
- ARI-3037MO was well absorbed orally and plasma levels demonstrated good dose proportionality
- ARI-3037MO showed encouraging lipid changes in both clinical trials in healthy subjects
Arisaph Pharmaceuticals, Inc. announced today during an oral presentation at the American Heart Association (AHA) meeting in Los Angeles, CA that its niacin analog, ARI-3037MO, was extremely well tolerated in a single-ascending dose (SAD) and a multiple-ascending dose (MAD) trial in healthy male and female volunteers. The results showed that ARI-3037MO did not provoke flushing or any other adverse skin changes, nor did it cause increases in liver enzymes or blood glucose at doses up to 6 grams per day. In both clinical trials, ARI-3037MO also demonstrated encouraging lipid effects. Based on these promising results, ARI-3037MO potentially represents a transformational, new niacin-like option for treatment of patients with dyslipidemia, especially in the setting of metabolic syndrome, a disorder that afflicts as many as 70 million Americans1.
"The absence of flushing and other niacin induced adverse events highlights a differentiated safety profile for our novel niacin analog," said Christopher P. Kiritsy, Co-Founder, President and Chief Executive Officer of Arisaph Pharmaceuticals. "Moreover, the evidence of lipid changes in such short duration trials in healthy volunteers shows that our preclinical efficacy data are translating and breeds optimism for the development of our best-in-class niacin analog."
In two placebo controlled, safety and pharmacokinetic trials (SAD and MAD), 58 healthy male and female volunteers were given either single escalating doses of ARI-3037MO (up to 6 grams per day) or repeat escalating doses of ARI-3037MO (up to 3.5 grams per day) for 14 days. In both trials, ARI-3037MO was given once daily without a titration scheme. The results showed that ARI-3037MO was extremely well tolerated with no treatment-related adverse events. Specifically, treatment with ARI-3037MO did not show any evidence of flushing or adverse skin changes, such as itching or rash, using a validated visual-analog scale. Additionally, no deleterious changes in liver enzymes or blood glucose were observed with ARI-3037MO, even when given at high doses in a repeat-dose setting.
The pharmacokinetics of ARI-3037MO revealed that the drug was well absorbed orally and showed good dose proportionality. In both clinical trials, ARI-3037MO produced encouraging lipid signals. For example, a single dose of 6 grams of ARI-3037MO produced a 15% increase in HDL and attenuated the postprandial increase in serum triglycerides (TGs). In the MAD trial, the 2g and 3.5g doses of ARI-3037MO decreased LDL-cholesterol (LDL-C) from baseline and improved post-prandial triglycerides by more than 30% compared with placebo. Such lipid trends are encouraging considering that the trials were short-duration, safety and pharmacokinetic studies in healthy volunteers and would not be expected to show pharmacodynamic effects.
"Niacin's efficacy across a broad range of lipid risk factors has long been recognized but flushing and increases in blood glucose have limited its use, particularly in high risk metabolic syndrome patients," commented Dr. Ernst Schaefer, Professor of Medicine, Tufts University School of Medicine. "The results from these two safety trials show that ARI-3037MO is devoid of such dose-limiting side effects, resulting in a significantly improved safety and tolerability profile compared with other niacin-based therapies."
In preclinical studies presented at the AHA in 2011, ARI-3037MO showed robust changes in lipids, including LDL-C, HDL-C and triglycerides. For example, once-daily treatments of ARI-3037MO lowered LDL-C in excess of 50% and lowered TGs by more than 70% compared with placebo in high-fat-fed hamster models. Additionally, non-clinical toxicology studies conducted in dogs and rats with ARI-3037MO showed that high exposure multiples could be achieved without serious adverse events, even at doses greater than 1000 mg per kilogram. The favorable preclinical safety and efficacy data reveal that ARI-3037MO has an extremely wide therapeutic index, indicating that ARI-3037MO will not be dose limited by adverse events. Consequently, it is expected that patients will be able to achieve improved efficacy observed with higher doses of niacin.
About Niacin Analog Program:
The natural B vitamin niacin is a well-known lipid lowering agent, which has been used to treat mixed lipid disorders for over 50 years. Niacin is a first-line drug for the treatment of hyperlipidemia, and it is used in combination with statins to further reduce LDL cholesterol and triglycerides or to increase HDL cholesterol in patients with depressed HDL cholesterol levels. Niacin can produce changes in HDL cholesterol up to 35%, lower LDL cholesterol up to 25% and lower triglycerides up to 50%. Despite niacin's broad lipid altering profile, the use of niacin-based therapies is diminished because of unpleasant side effects, particularly flushing. Flushing, representative of tingling and/or redness of the skin, is the principal side effect of niacin, and in some patients it can be extremely uncomfortable. Arisaph has developed a novel class of structural analogs of niacin that are expected to demonstrate a dramatically improved safety and tolerability profile while retaining the beneficial lipid effects associated with niacin.
Arisaph Pharmaceuticals Inc, a drug discovery, biopharmaceutical company located in Boston, Massachusetts, was founded by Dr. William Bachovchin (Professor of Biochemistry, Tufts University School of Medicine), Christopher Kiritsy (Former EVP Corporate Development and CFO, Kos Pharmaceuticals, Inc.) and Michael Jaharis (Founder, Chairman Emeritus, Kos Pharmaceuticals, Inc.) to develop differentiated therapies for cardiometabolic diseases and cancer. Arisaph has developed a rich pipeline of products at various stages of development, including a niacin analog (ARI-3037MO), in phase 2 clinical development, and a small molecule immune modulator for the treatment of cancer. The Company's vision is to create a fully integrated pharmaceutical company, leveraging its drug discovery expertise to develop transformational, patent protected, medicines that offer distinct safety, efficacy and/or tolerability benefits compared with existing therapies for large markets, whose needs are not being fully met by current therapeutics.
Certain statements in this press release, including statements regarding the Company's research and development effort, the Company's expectation to initiate or complete human clinical studies, the Company's ability to finance its development programs into human clinical testing, and the Company's ability to successfully capitalize on the early stage research are subject to risks and uncertainties. These risks and uncertainties include risks and uncertainties related to: our ability to discover and develop new compounds and products using a novel approach to drug discovery; the early stage of all of our discovery and development efforts; our ability to complete preclinical and clinical development of our products; our ability to obtain and maintain regulatory approvals for our products; competition from other technologies and technologies similar to ours; obtaining, maintaining and protecting intellectual property utilized by our products; changes in legislation and regulations affecting our products and potential product candidates; our need to obtain additional funding to support our business activities; our dependence on collaborators and other third parties for development, manufacture, marketing, sales and distribution of products; the ability of our licensees to achieve developmental, regulatory and other milestones and to commercialize their products; the effect of conditions in the pharmaceutical industry and the economy in general, as well as certain other risks and uncertainties.
1. NHANES Data, National Health Statistics Report, May 2009
Arisaph Pharmaceuticals, Inc.
President and CEO
SOURCE Arisaph Pharmaceuticals, Inc.
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists will examine how DevOps helps to meet th...
Apr. 25, 2017 12:30 PM EDT Reads: 1,115
SYS-CON Events announced today that Hitachi, the leading provider the Internet of Things and Digital Transformation, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Hitachi Data Systems, a wholly owned subsidiary of Hitachi, Ltd., offers an integrated portfolio of services and solutions that enable digital transformation through enhanced data management, governance, mobility and analytics. We help globa...
Apr. 25, 2017 12:15 PM EDT Reads: 898
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain.
Apr. 25, 2017 12:15 PM EDT Reads: 2,489
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
Apr. 25, 2017 12:00 PM EDT Reads: 839
@DevOpsSummit has been named the ‘Top DevOps Influencer' by iTrend. iTred processes millions of conversations, tweets, interactions, news articles, press releases, blog posts - and extract meaning form them and analyzes mobile and desktop software platforms used to communicate, various metadata (such as geo location), and automation tools. In overall placement, @DevOpsSummit ranked as the number one ‘DevOps Influencer' followed by @CloudExpo at third, and @MicroservicesE at 24th.
Apr. 25, 2017 12:00 PM EDT Reads: 2,697
The goal of Continuous Testing is to shift testing left to find defects earlier and release software faster. This can be achieved by integrating a set of open source functional and performance testing tools in the early stages of your software delivery lifecycle. There is one process that binds all application delivery stages together into one well-orchestrated machine: Continuous Testing. Continuous Testing is the conveyor belt between the Software Factory and production stages. Artifacts are ...
Apr. 25, 2017 11:30 AM EDT Reads: 1,044
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Apr. 25, 2017 11:30 AM EDT Reads: 254
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...
Apr. 25, 2017 11:30 AM EDT Reads: 4,806
The age of Digital Disruption is evolving into the next era – Digital Cohesion, an age in which applications securely self-assemble and deliver predictive services that continuously adapt to user behavior. Information from devices, sensors and applications around us will drive services seamlessly across mobile and fixed devices/infrastructure. This evolution is happening now in software defined services and secure networking. Four key drivers – Performance, Economics, Interoperability and Trust ...
Apr. 25, 2017 11:30 AM EDT Reads: 244
Quickly find the root cause of complex database problems slowing down your applications. Up to 88% of all application performance issues are related to the database. DPA’s unique response time analysis shows you exactly what needs fixing - in four clicks or less. Optimize performance anywhere. Database Performance Analyzer monitors on-premises, on VMware®, and in the Cloud, including Amazon® AWS and Azure™ virtual machines.
Apr. 25, 2017 11:30 AM EDT Reads: 1,779
Back in February of 2017, Andrew Clay Schafer of Pivotal tweeted the following: “seriously tho, the whole software industry is stuck on deployment when we desperately need architecture and telemetry.” Intrigue in a 140 characters. For me, I hear Andrew saying, “we’re jumping to step 5 before we’ve successfully completed steps 1-4.”
Apr. 25, 2017 11:15 AM EDT Reads: 1,595
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
Apr. 25, 2017 10:30 AM EDT Reads: 364
Five years ago development was seen as a dead-end career, now it’s anything but – with an explosion in mobile and IoT initiatives increasing the demand for skilled engineers. But apart from having a ready supply of great coders, what constitutes true ‘DevOps Royalty’? It’ll be the ability to craft resilient architectures, supportability, security everywhere across the software lifecycle. In his keynote at @DevOpsSummit at 20th Cloud Expo, Jeffrey Scheaffer, GM and SVP, Continuous Delivery Busine...
Apr. 25, 2017 10:30 AM EDT Reads: 628
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
Apr. 25, 2017 10:15 AM EDT Reads: 2,091
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
Apr. 25, 2017 10:00 AM EDT Reads: 938